News | April 28, 2026
Essilor Stellest lens positioned as key breakthrough in myopia control in India
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
Subscribe To Our Newsletter & Stay Updated
